Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarek Assi

Showing results (31-40 of 120) with videos related to

Pageof 12
Sort By:
Future Oncology (London, England)|July 19, 2016
Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicineFouad Aoun, Elie El Rassy, Tarek Assi, et al.
Bulletin Du Cancer|May 11, 2019
Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologistsElie El Rassy, Tarek Assi, Joseph Kattan, et al.
Pharmacology & Therapeutics|September 5, 2021
Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approachAli N Chamseddine, Tarek Assi, Olivier Mir, et al.
Oncology Research and Treatment|May 8, 2020
Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive ReviewTarek Assi, Elie Rassy, Fadi Farhat, et al.
Diagnostics (Basel, Switzerland)|June 24, 2022
Posterior Reversible Encephalopathy Syndrome Following Chemotherapy and Immune Checkpoint Inhibitor Combination in a Patient with Small-Cell Lung CancerCécile Evin, Nathalie Lassau, Corinne Balleyguier, et al.
Personalized Medicine|June 27, 2020
Epithelioid sarcoma as the prototype for personalized therapy in soft tissue sarcomaTarek Assi, Elie Rassy, Hussein Nassereddine, et al.
Immunotherapy|November 16, 2024
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?Tarek Assi, Mohamad Ali Hachem, Roula Amine-Hneineh, et al.
Future Oncology (London, England)|November 26, 2024
Artificial intelligence and radiomics in desmoid-type fibromatosis: are we there yet?Tania Moussa, Tarek Assi, Ines Kasraoui, et al.
Immunotherapy|March 31, 2017
Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatmentFouad Aoun, Elie El Rassy, Tarek Assi, et al.
Bulletin Du Cancer|January 30, 2017
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agentsMarwan Ghosn, Tarek Assi, Elie El Rassy, et al.
Pageof 12

Showing results (31-40 of 120) with videos related to

Sort By:
Pageof 12
Future Oncology (London, England)|July 19, 2016
Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicineFouad Aoun, Elie El Rassy, Tarek Assi, et al.
Bulletin Du Cancer|May 11, 2019
Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologistsElie El Rassy, Tarek Assi, Joseph Kattan, et al.
Pharmacology & Therapeutics|September 5, 2021
Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approachAli N Chamseddine, Tarek Assi, Olivier Mir, et al.
Oncology Research and Treatment|May 8, 2020
Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive ReviewTarek Assi, Elie Rassy, Fadi Farhat, et al.
Diagnostics (Basel, Switzerland)|June 24, 2022
Posterior Reversible Encephalopathy Syndrome Following Chemotherapy and Immune Checkpoint Inhibitor Combination in a Patient with Small-Cell Lung CancerCécile Evin, Nathalie Lassau, Corinne Balleyguier, et al.
Personalized Medicine|June 27, 2020
Epithelioid sarcoma as the prototype for personalized therapy in soft tissue sarcomaTarek Assi, Elie Rassy, Hussein Nassereddine, et al.
Immunotherapy|November 16, 2024
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?Tarek Assi, Mohamad Ali Hachem, Roula Amine-Hneineh, et al.
Future Oncology (London, England)|November 26, 2024
Artificial intelligence and radiomics in desmoid-type fibromatosis: are we there yet?Tania Moussa, Tarek Assi, Ines Kasraoui, et al.
Immunotherapy|March 31, 2017
Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatmentFouad Aoun, Elie El Rassy, Tarek Assi, et al.
Bulletin Du Cancer|January 30, 2017
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agentsMarwan Ghosn, Tarek Assi, Elie El Rassy, et al.
Pageof 12